
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRP19 CRISPR/Cas9 KO Plasmid (h) | sc-404130 | 20 µg | $397.00 | |||
PRP19 HDR Plasmid (h) | sc-404130-HDR | 20 µg | $445.00 |
PRPF19 encodes PRP19, a core component of the PRP19/NTC spliceosomal complex that stabilizes the activated spliceosome and supports pre-mRNA splicing fidelity. PRP19 also functions as an E3 ubiquitin ligase and participates in the DNA damage response, linking RNA processing with genome maintenance pathways. Through coordination of spliceosome remodeling, ubiquitin signaling, and stress-responsive checkpoints, PRP19 influences transcriptome integrity and cell-cycle progression. Dysregulation of PRPF19-associated splicing and repair processes has been connected to altered gene expression programs and genomic instability relevant to cancer biology and neurodegeneration research.
PRP19 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PRPF19 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the PRPF19 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, PRP19 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined PRPF19 target site.
When co-transfected with PRP19 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the PRPF19 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.